SurModics Has Returned 21.1% Since SmarTrend Recommendation (SRDX)
Comtex SmarTrend(R) - Mon Feb 09, 9:48AM CST
SmarTrend identified an Uptrend for SurModics (NASDAQ:SRDX) on October 8th, 2014 at $19.91. In approximately 4 months, SurModics has returned 21.09% as of today's recent price of $24.11.
SRDX: 23.53 (+0.10)
SurModics Announces Gerald B. Fischer's Retirement from Board of Directors
Business Wire - Thu Feb 05, 3:15PM CST
SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industries, today announced that Gerald B. (Jerry) Fischer has retired from the board of directors, effective immediately. Fischer is stepping down for personal health reasons. Following Fischer's retirement, the SurModics board now consists of eight members, seven of whom are independent. At present, the board does not intend to fill the vacancy created as a result of Fischer's retirement as it is the Company's intention to reduce the size of the Board over time.
SRDX: 23.53 (+0.10)
SurModics to Webcast Shareholders Annual Meeting on February 10
Business Wire - Tue Feb 03, 7:01AM CST
SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that it will host a live webcast of its Annual Meeting of Shareholders on Tuesday, February 10, at 4:00 p.m. CT (5:00 p.m. ET).
SRDX: 23.53 (+0.10)
SurModics Up 15.7% Since SmarTrend Uptrend Call (SRDX)
Comtex SmarTrend(R) - Mon Feb 02, 9:28AM CST
SmarTrend identified an Uptrend for SurModics (NASDAQ:SRDX) on October 8th, 2014 at $19.91. In approximately 4 months, SurModics has returned 15.67% as of today's recent price of $23.03.
SRDX: 23.53 (+0.10)
SurModics reaffirms FY2015 guidance after FQ1
Seeking Alpha - at Seeking Alpha - Fri Jan 30, 9:33AM CST
SRDX: 23.53 (+0.10)
SurModics Beats on Q1 Earnings, Reaffirms 2015 Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 9:20AM CST
SurModics, Inc.'s first-quarter fiscal 2015 (ended Dec 31, 2014) adjusted earnings of 25 cents per share beat the Zacks Consensus Estimate by 4 cents.
SRDX: 23.53 (+0.10), AMAG: 41.49 (+0.23), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
SurModics' (SRDX) CEO Gary Maharaj on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Jan 29, 11:26PM CST
SRDX: 23.53 (+0.10)
SurModics (SRDX) Q1 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Jan 29, 3:55PM CST
SRDX: 23.53 (+0.10)
SurModics beats by $0.04, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 3:25PM CST
SRDX: 23.53 (+0.10)
SurModics Reports First Quarter Fiscal 2015 Results
Business Wire - Thu Jan 29, 3:15PM CST
--SurModics SurVeil(TM) Drug Coated Balloon GLP Study Underway
SRDX: 23.53 (+0.10)
SurModics: Let This Surface Modification Company Modify Your Portfolio
Ravi Ramenani - at Seeking Alpha - Thu Jan 22, 1:34PM CST
SRDX: 23.53 (+0.10)
SurModics to Webcast First Quarter 2015 Earnings Conference Call on January 29
Business Wire - Tue Jan 20, 7:02AM CST
SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, announced today that it will host a live webcast of its first quarter 2015 conference call on Thursday, January 29, at 4:00 p.m. CT (5:00 p.m. ET). The Company will issue an earnings news release after the market closes that afternoon.
SRDX: 23.53 (+0.10)
SurModics approves USD20m share repurchase programme
M2 - Thu Nov 13, 7:03AM CST
In vitro diagnostic technologies company SurModics (NasdaqGS:SRDX) reported on Wednesday the launch of a USD20m accelerated share repurchase plan.
SRDX: 23.53 (+0.10), WFC: 55.33 (+0.47)
SurModics initiates accelerated share buyback
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 9:06AM CST
SRDX: 23.53 (+0.10)
SurModics Announces Accelerated Share Repurchase Program
Business Wire - Wed Nov 12, 7:01AM CST
SurModics, Inc. (NASDAQ:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industries, today announced that it has entered into a $20 million accelerated share repurchase program.
SRDX: 23.53 (+0.10)
SurModics Beats on Q4 Earnings, Issues Fiscal 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 9:10AM CST
SurModics, Inc.???s fourth-quarter fiscal 2014 adjusted earnings of 26 cents per share beat the Zacks Consensus Estimate by a penny.
AGN: 229.49 (+1.87), SRDX: 23.53 (+0.10), ABAX: 60.93 (+0.65), ABBV: 58.05 (+1.00)
SurModics' (SRDX) CEO Gary Maharaj Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 8:42PM CST
SRDX: 23.53 (+0.10)
SurModics beats by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:51PM CST
SRDX: 23.53 (+0.10)
SurModics Reports Fourth Quarter Fiscal 2014 Results
Business Wire - Thu Nov 06, 3:15PM CST
--Design Freeze on Paclitaxel Drug Coated Balloon Development
SRDX: 23.53 (+0.10)
SurModics reports November 6
Seeking Alpha - at Seeking Alpha - Sat Nov 01, 5:28PM CDT
SRDX: 23.53 (+0.10)